BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS
|
|
- Monica Lamb
- 6 years ago
- Views:
Transcription
1 : TECHNOLOGIES AND GLOBAL MARKETS BIO061C April 2014 Jackson Highsmith Project Analyst ISBN: BCC Research 49 Walnut Park, Building 2 Wellesley, MA USA (toll-free within the USA), or (+1) information@bccresearch.com
2 TABLE OF CONTENTS CHAPTER 1 INTRODUCTION 2 STUDY GOALS AND OBJECTIVES 2 REASONS FOR DOING THE STUDY 2 SCOPE OF REPORT 2 INTENDED AUDIENCE 3 METHODOLOGY AND INFORMATION SOURCES 4 ANALYST'S CREDENTIALS 4 RELATED BCC RESEARCH REPORTS 4 BCC RESEARCH WEBSITE 5 DISCLAIMER 5 CHAPTER 2 SUMMARY 7 SUMMARY TABLE GLOBAL FORECAST BY SEGMENT, THROUGH 2018 ($ MILLIONS) SUMMARY FIGURE GLOBAL FORECAST BY SEGMENT, ($ MILLIONS) 7 7 CHAPTER 3 OVERVIEW 11 INTRODUCTION 11 TABLE 1 GLOBAL MARKET FOR, THROUGH 2013 ($ MILLIONS) 12 ENABLING ADVANCEMENTS DRIVING MARKET GROWTH 12 DRIVE SPEED, COST AND QUALITY IMPROVEMENTS ACROSS THE DRUG DEVELOPMENT SPECTRUM COST REDUCTION OPPORTUNITIES ARISING FROM BIOMARKER APPLICATIONS Elements of Cost in Healthcare 14 STRATEGIC BIOMARKER APPLICATIONS 15 Targeted Therapies 15 Product Extensions 16 Ultra-Blockbuster 17 BIOMARKER APPLICATIONS: DRUG DEVELOPMENT 17 Safety/Toxicology Biomarkers 18 TABLE 2 NOVEL SAFETY/TOXICOLOGY USED IN CANCER, CARDIO AND RENAL Dose Selection and Dose Optimization 19 TABLE 3 NOVEL DOSE SELECTION USED IN CANCER, DIABETES, METABOLIC AND LIVER DISEASE Improved Measurement of Therapeutic Efficacy 20 Outcome Biomarkers and Surrogate Endpoints 21 TABLE 4 PATIENT OUTCOME MEASUREMENTS 21 EARLY-STAGE CLINICAL TRIAL APPLICATIONS 21 LATE-STAGE CLINICAL TRIAL APPLICATIONS 22 Phase III 22 Phase IV 22 : CHALLENGES AND OPPORTUNITIES 22 SUMMARY 22 CHALLENGES
3 OPPORTUNITIES 25 CLINICAL VALIDITY: REQUIREMENTS 26 BIOMARKER OPPORTUNITIES 26 PRODUCT SUMMARY AND MARKET 26 GENOMICS 26 TABLE 5 GLOBAL MARKET FOR, 2013 ($ MILLIONS) 27 IMAGING 27 PROTEOMICS 27 BIOINFORMATICS 28 OTHER 29 Metabolomics 29 BIOMARKER ADOPTION BY THE PHARMACEUTICAL INDUSTRY 29 GROWTH DRIVERS AND RESISTORS 29 FACTORS INFLUENCING BIOMARKER ADOPTION IN CLINICAL TRIALS 29 CLINICAL TRIAL BENEFITS: COST AND RISK AVOIDANCE 30 IMPACT OF DRUG FAILURE IN LATE-STAGE CLINICAL TRIALS 30 Merck: Vicriviroc 30 Myriad: Flurizan 31 ADDITIONAL CAPABILITIES BY LARGE SERVICE PLAYERS 31 TECHNOLOGICAL ADVANCEMENTS IN GENOMICS AND PROTEOMICS 31 BIOMARKER MARKET FORECAST 31 TABLE 6 GLOBAL BIOMARKER MARKET FORECAST, THROUGH 2018 ($ MILLIONS) 32 CHAPTER 4 REGULATORY DYNAMICS, INTELLECTUAL PROPERTY AND ETHICAL CONSIDERATIONS INTRODUCTION 34 BIOMARKER LABORATORY REGULATORY SUMMARY 34 DEFINITION OF AN IVD COMPANION DIAGNOSTIC 35 Labeling 37 Investigational Use 38 MINI REVIEW OF FDA GUIDANCE ON APPROVAL OF THE COMPANION DIAGNOSTIC Summary 38 Timing Considerations 39 Regulatory Pathways Outside of the United States (k) vs PMA 40 ASSAY DEVELOPMENT AND VALIDATION IN DRUG DIAGNOSTIC CO-DEVELOPMENT Overview 41 General Considerations in Drug Diagnostic Co-Development 42 Implementation of Companion Diagnostic in Clinical Design 42 Two-Arm Clinical Design 43 Randomization with the Diagnostic 43 Restricted Approach 44 Establishing a Training and Test Set of Samples 45 Patient Population Consistency 45 Iterative Evaluation Cycles 46 Clinical Material Considerations
4 Technical Considerations 47 Testing Volume 47 Ease of Use 48 Number of Analytes 48 Multiple Analyte versus Few Analyte Classifiers 49 Instrument 50 Reagent Status 51 Assay Validation 51 Assay Characterization or Qualification 51 Analytical Validation of a Companion Diagnostic 52 Studies to Demonstrate Accuracy, Precision, Specificity and Sensitivity Sample Requirements 54 Analyte Concentration Specifications 54 Cutoff Establishment 54 Controls and Calibrators 55 Precision 56 Analytical Specificity 56 Assay Conditions 57 Sample Carryover 57 Limiting Factors 57 CLINICAL VALIDATION 57 ROLE OF THE FOOD AND DRUG ADMINISTRATION 58 TABLE 7 FDA GUIDELINES FOR BIOMARKER APPLICATIONS 59 EUROPEAN MEDICINES AGENCY 60 REGULATORY IMPACT ON DRUG SAFETY 60 INTELLECTUAL PROPERTY AND COMPETITIVE POSITIONING 61 APPROVED PATENT ANALYSIS 61 TABLE 8 ANNUAL PATENTS FILED AND APPROVED WITH BIOMARKER CLAIMS IN THE U.S., EUROPE AND JAPAN, THROUGH 2013 COMPETITIVE LANDSCAPE 61 LATE-STAGE CLINICAL TRIALS: COMPETITIVE POSITIONING 62 TABLE 9 CURRENT GLOBAL MARKET FOR TOTAL CLINICAL STAGE BY SERVICES AND PRODUCTS, THROUGH 2018 ($ MILLIONS) TABLE 10 SUMMARY OF RECENT AGREEMENTS IN BIOMARKER DELIVERY, TABLE 11 REPRESENTATIVE LIST OF INDUSTRY ADVANCEMENTS AND APPROVED BIOMARKER PATENTS IN THE U.S., EUROPE AND JAPAN ETHICAL CONSIDERATIONS 69 SUMMARY 69 Respect for Persons 71 Beneficence 71 Justice 72 BIOMARKER APPLICATIONS OF ETHICAL CONSIDERATIONS 72 Race and Genotype 72 Negligence 72 Informed Consent 73 Privacy
5 Market Segmentation 74 Professional, Media and Opinion Leader Edification 74 REGULATORY IMPLICATIONS 75 CHAPTER 5 APPLICATION BY THERAPY AREA 77 TABLE 12 GLOBAL MARKET FOR CLINICAL STAGE BY THERAPEUTIC AREA, THROUGH 2018 ($ MILLIONS) ONCOLOGY 80 TABLE 13 REPRESENTATIVE IN CLINICAL USE: ONCOLOGY 81 BREAST CANCER 81 MAMMAPRINT 82 TABLE 14 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: BREAST CANCER ONCOTYPE DX 83 TEST ADOPTION 84 COLORECTAL CANCER 86 CETUXIMAB 86 PANITUMUMAB 88 ELESCLOMOL 90 HERCEPTIN 90 OTHER PREDICTIVE TESTS 90 TABLE 15 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: ONCOLOGY, OTHER PROGNOSTIC TESTS 92 PREDICTIVE TESTS IN BREAST CANCER 94 HORMONAL THERAPIES 94 TAXANES/ANTHRACYCLINES 96 BIOLOGICALS 98 TRIPLE NEGATIVE BREAST CANCER 99 OTHER NOVEL 100 LUNG CANCER 101 INTRODUCTION 101 PREDICTIVE TESTS 102 TABLE 16 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: LUNG CANCER 102 GEFITINIB 103 ERLOTINIB 104 OTHER PREDICTIVE TESTS 106 NOVEL THERAPIES 106 OTHER ONCOLOGY 107 PROSTATE CANCER 107 OVARIAN CANCER 109 MALIGNANT MELANOMA 109 TABLE 17 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: MALIGNANT MELANOMA OTHER DISEASES 111 CARDIOVASCULAR 111 TABLE 18 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: CARDIOVASCULAR
6 TABLE 19 REPRESENTATIVE IN CLINICAL USE: CARDIOVASCULAR 113 CENTRAL NERVOUS SYSTEM 113 TABLE 20 REPRESENTATIVE IN CLINICAL USE: CNS DISEASE 115 IMMUNOLOGY 115 TABLE 21 REPRESENTATIVE IN CLINICAL USE: IMMUNOLOGY 116 Immunology: Benlysta: Human Genome Sciences 116 EXPEDITION and IDENTITY Alzheimer's Trial: Eli Lilly 117 CLINICAL : THERAPEUTIC DISEASE MARKET FORECAST 117 TABLE 22 GLOBAL MARKET FORECAST FOR CLINICAL STAGE, THROUGH 2018 ($ MILLIONS) TABLE 23 GLOBAL MARKET FORECAST OF IN LATE-STAGE CLINICAL USE BY THERAPEUTIC AREA, THROUGH 2018 ($ MILLIONS) CHAPTER 6 ACTIVELY GUIDING DRUG DEVELOPMENT 119 INTRODUCTION 119 TABLE 24 RECENT CORPORATE ALLIANCES BETWEEN BIOMARKER AND DRUG DEVELOPMENT COMPANIES ASURAGEN 120 BACKGROUND 120 COLLABORATION: MERCK & CO. 121 BG MEDICINE 121 BACKGROUND 121 COLLABORATION: CORDEX PHARMA 121 COLLABORATION: SIEMENS 121 BIOMERIEUX 122 BACKGROUND 122 COLLABORATIONS: ISPEN 122 ADNA PROJECT 122 CELERA 124 BACKGROUND 124 COLLABORATIONS 124 Abbott 124 Merck & Co. 124 Ipsen 124 AVACTA 125 BACKGROUND 125 COLLABORATION: TAKEDA 125 DAKO 125 BACKGROUND 125 COLLABORATIONS 125 Genentech 125 Bristol-Myers Squibb 126 DXS 126 BACKGROUND 126 COLLABORATIONS 127 Amgen 127 Roche Molecular Diagnostics 127 GE HEALTHCARE
7 BACKGROUND 128 COLLABORATION: ELI LILLY 128 GENOMIC HEALTH 128 BACKGROUND 128 COLLABORATIONS 128 Pfizer 128 Bristol-Myers Squibb and ImClone Systems 129 HISTORX 129 BACKGROUND 129 COLLABORATION 129 Lilly 129 LABCORP 130 BACKGROUND 130 COLLABORATIONS 130 ARCA biopharma 130 Vanda Pharmaceuticals 131 Medco Health Solutions 132 MONOGRAM BIOSCIENCES (A LABCORP COMPANY) 132 BACKGROUND 132 COLLABORATIONS 132 Pfizer HIV partnership 132 VeraTag Oncology Platform 132 ONCOMETHYLOME SCIENCES (NOW MDX HEALTH) 133 BACKGROUND 133 COLLABORATIONS 133 Merck KGaA 133 Schering-Plough 133 GlaxoSmithKline Biologicals 133 Abbott 134 XDX 134 BACKGROUND 134 COLLABORATION 134 Bristol-Myers Squibb 134 CHAPTER 7 COMPANY ANALYSIS 136 TABLE 25 PRINCIPAL FOCUS OF : PHARMACEUTICAL COMPANIES BY THERAPEUTIC AREA ABBOTT LABORATORIES INC. 136 COMPANY OVERVIEW 136 PRODUCTS AND SERVICES 136 TABLE 26 ABBOTT: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING COMPANY STRATEGY 137 AFFYMETRIX INC. 138 COMPANY OVERVIEW 138 PRODUCTS AND SERVICES 138 TABLE 27 AFFYMETRIX: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING
8 COMPANY STRATEGY 138 ASTELLAS PHARMA INC. 139 COMPANY OVERVIEW 139 PRODUCTS AND SERVICES 139 TABLE 28 ASTELLAS: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING COMPANY STRATEGY 140 ASTRAZENECA LTD. 140 COMPANY OVERVIEW 141 PRODUCTS AND SERVICES 141 TABLE 29 ASTRAZENECA: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING COMPANY STRATEGY 142 BANYAN INC. 142 COMPANY OVERVIEW 142 PRODUCTS AND SERVICES 142 TABLE 30 BANYAN: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING COMPANY STRATEGY 143 BAYER SCHERING PHARMA AG 143 COMPANY OVERVIEW 143 PRODUCTS AND SERVICES 143 TABLE 31 BAYER SCHERING: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING COMPANY STRATEGY 144 BG MEDICINE INC. 146 COMPANY OVERVIEW 146 PRODUCTS AND SERVICES 146 TABLE 32 BIOPHYSICAL: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING COMPANY STRATEGY 146 BIOPHYSICAL CORP. 147 COMPANY OVERVIEW 147 PRODUCTS AND SERVICES 147 TABLE 33 BIOSYSTEMS: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING COMPANY STRATEGY 148 BIOSYSTEMS INTERNATIONAL INC. 148 COMPANY OVERVIEW 148 PRODUCTS AND SERVICES 149 COMPANY STRATEGY 149 BOEHRINGER INGELHEIM GMBH 149 COMPANY OVERVIEW 149 PRODUCTS AND SERVICES 149 TABLE 34 BMS: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING COMPANY STRATEGY 150 BRISTOL-MYERS SQUIBB CO. 150 COMPANY OVERVIEW
9 PRODUCTS AND SERVICES 151 TABLE 35 BMS: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING COMPANY STRATEGY 151 CAPRION PROTEOMICS INC. 152 COMPANY OVERVIEW 152 PRODUCTS AND SERVICES 152 COMPANY STRATEGY 153 Infectious Diseases 153 Diabetes and Metabolic Disease 153 Oncology 153 DAIICHI SANKYO CO. LTD. 154 COMPANY OVERVIEW 154 PRODUCTS AND SERVICES 154 TABLE 36 DAIICHI SANKYO: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING COMPANY STRATEGY 155 EISAI CO. LTD. 155 COMPANY OVERVIEW 156 PRODUCTS AND SERVICES 156 TABLE 37 EISAI: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING COMPANY STRATEGY 156 ELI LILLY AND CO. 157 COMPANY OVERVIEW 157 PRODUCTS AND SERVICES 157 TABLE 38 ELI LILLY: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING COMPANY STRATEGY 158 EPIGENOMICS AG 158 COMPANY OVERVIEW 158 PRODUCTS AND SERVICES 159 TABLE 39 EPIGENOMICS: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING COMPANY STRATEGY 159 GENEDATA AG 160 COMPANY OVERVIEW 160 PRODUCTS AND SERVICES 160 TABLE 40 GENEDATA AG: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING COMPANY STRATEGY 160 GENENEWS LTD. 161 COMPANY OVERVIEW 161 PRODUCTS AND SERVICES 161 COMPANY STRATEGY 161 GLAXOSMITHKLINE 162 COMPANY OVERVIEW 162 PRODUCTS AND SERVICES
10 TABLE 41 GSK: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING COMPANY STRATEGY 163 JOHNSON & JOHNSON LTD. 163 COMPANY OVERVIEW 163 PRODUCTS AND SERVICES 164 TABLE 42 JOHNSON & JOHNSON: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING COMPANY STRATEGY 164 MERCK & CO. 165 COMPANY OVERVIEW 165 PRODUCTS AND SERVICES 165 TABLE 43 MERCK: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING COMPANY STRATEGY 166 NOVARTIS AG 166 COMPANY OVERVIEW 166 PRODUCTS AND SERVICES 167 TABLE 44 NOVARTIS: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING COMPANY STRATEGY 167 PFIZER INC. 168 COMPANY OVERVIEW 168 PRODUCTS AND SERVICES 168 TABLE 45 PFIZER: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING COMPANY STRATEGY 169 ROCHE LTD. 169 COMPANY OVERVIEW 169 PRODUCTS AND SERVICES 169 TABLE 46 ROCHE: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING COMPANY STRATEGY 170 SANOFI-AVENTIS 171 COMPANY OVERVIEW 171 PRODUCTS AND SERVICES 171 TABLE 47 SANOFI-AVENTIS: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING COMPANY STRATEGY 172 TAKEDA PHARMACEUTICALS LTD. 173 COMPANY OVERVIEW 173 PRODUCTS AND SERVICES 173 TABLE 48 TAKEDA PHARMACEUTICALS: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING COMPANY STRATEGY 174 TEVA PHARMACEUTICAL INDUSTRIES LTD. 174 COMPANY OVERVIEW 174 PRODUCTS AND SERVICES
11 TABLE 49 TEVA PHARMACEUTICAL: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING COMPANY STRATEGY
12 LIST OF TABLES TABLE HEADING SUMMARY TABLE GLOBAL FORECAST BY SEGMENT, THROUGH 2018 ($ MILLIONS) TABLE 1 GLOBAL MARKET FOR, THROUGH 2013 ($ MILLIONS) 12 TABLE 2 NOVEL SAFETY/TOXICOLOGY USED IN CANCER, CARDIO AND RENAL TABLE 3 NOVEL DOSE SELECTION USED IN CANCER, DIABETES, METABOLIC AND LIVER DISEASE TABLE 4 PATIENT OUTCOME MEASUREMENTS 21 TABLE 5 GLOBAL MARKET FOR, 2013 ($ MILLIONS) 27 TABLE 6 GLOBAL BIOMARKER MARKET FORECAST, THROUGH 2018 ($ MILLIONS) 32 TABLE 7 FDA GUIDELINES FOR BIOMARKER APPLICATIONS 59 TABLE 8 ANNUAL PATENTS FILED AND APPROVED WITH BIOMARKER CLAIMS IN THE U.S., EUROPE AND JAPAN, THROUGH 2013 TABLE 9 CURRENT GLOBAL MARKET FOR TOTAL CLINICAL STAGE BY SERVICES AND PRODUCTS, THROUGH 2018 ($ MILLIONS) TABLE 10 SUMMARY OF RECENT AGREEMENTS IN BIOMARKER DELIVERY, TABLE 11 REPRESENTATIVE LIST OF INDUSTRY ADVANCEMENTS AND APPROVED BIOMARKER PATENTS IN THE U.S., EUROPE AND JAPAN TABLE 12 GLOBAL MARKET FOR CLINICAL STAGE BY THERAPEUTIC AREA, THROUGH 2018 ($ MILLIONS) TABLE 13 REPRESENTATIVE IN CLINICAL USE: ONCOLOGY 81 TABLE 14 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: BREAST CANCER 83 TABLE 15 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: ONCOLOGY, TABLE 16 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: LUNG CANCER 102 TABLE 17 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: MALIGNANT MELANOMA TABLE 18 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: CARDIOVASCULAR TABLE 19 REPRESENTATIVE IN CLINICAL USE: CARDIOVASCULAR 113 TABLE 20 REPRESENTATIVE IN CLINICAL USE: CNS DISEASE 115 TABLE 21 REPRESENTATIVE IN CLINICAL USE: IMMUNOLOGY 116 TABLE 22 GLOBAL MARKET FORECAST FOR CLINICAL STAGE, THROUGH 2018 ($ MILLIONS) TABLE 23 GLOBAL MARKET FORECAST OF IN LATE-STAGE CLINICAL USE BY THERAPEUTIC AREA, THROUGH 2018 ($ MILLIONS) TABLE 24 RECENT CORPORATE ALLIANCES BETWEEN BIOMARKER AND DRUG DEVELOPMENT COMPANIES TABLE 25 PRINCIPAL FOCUS OF : PHARMACEUTICAL COMPANIES BY THERAPEUTIC AREA TABLE 26 ABBOTT: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING TABLE 27 AFFYMETRIX: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING TABLE 28 ASTELLAS: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING TABLE 29 ASTRAZENECA: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING TABLE 30 BANYAN: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING
13 TABLE HEADING TABLE 31 BAYER SCHERING: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING TABLE 32 BIOPHYSICAL: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING TABLE 33 BIOSYSTEMS: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING TABLE 34 BMS: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING TABLE 35 BMS: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING TABLE 36 DAIICHI SANKYO: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING TABLE 37 EISAI: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING TABLE 38 ELI LILLY: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING TABLE 39 EPIGENOMICS: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING TABLE 40 GENEDATA AG: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING TABLE 41 GSK: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING TABLE 42 JOHNSON & JOHNSON: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING TABLE 43 MERCK: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING TABLE 44 NOVARTIS: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING TABLE 45 PFIZER: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING TABLE 46 ROCHE: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING TABLE 47 SANOFI-AVENTIS: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING TABLE 48 TAKEDA PHARMACEUTICALS: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING TABLE 49 TEVA PHARMACEUTICAL: REPRESENTATIVE UPDATES AND CLINICAL TRIALS INVOLVING
14 LIST OF FIGURES FIGURE TITLE SUMMARY FIGURE GLOBAL FORECAST BY SEGMENT, ($ MILLIONS) 7
PROTEOMICS: TECHNOLOGIES AND GLOBAL MARKETS. BIO034C May John Bergin Project Analyst ISBN:
PROTEOMICS: TECHNOLOGIES AND GLOBAL MARKETS BIO034C May 2013 John Bergin Project Analyst ISBN: 1-56965-403-4 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 866-285-7215, 781-489-7301 www.bccresearch.com
More informationRoche, Roche Molecular Diagnostics and more
, Molecular and more [Monte Wetzel, PhD] Patients have questions. We provide answers. Group Clear focus on Healthcare Innovation with two strong pillars Pharma Pharma Genentech Chugai Molecular Professional
More informationFuture of Molecular Diagnostics: Innovative Technologies Driving Market Opportunities
Future of Molecular Diagnostics: Innovative Technologies Driving Market Opportunities Introduction The report analyzes current and potential world molecular diagnostics markets and advances in the field.
More informationRoche in Australia Innovation Leader
Roche in Australia Innovation Leader About Roche Innovation: it s in our DNA 7,000,874 hours of work 6,587 experiments 423 researchers 1 drug For nearly 120 years, Roche has been committed to improving
More informationImmunotoxicology Technical Committee (ITC) HESI Assembly of Members January 19, 2009
Immunotoxicology Technical Committee (ITC) HESI Assembly of Members January 19, 2009 Committee Leadership Dr. Ellen Evans (Schering-Plough Research Institute), Chair Dr. Tom Kawabata (Pfizer Inc.), Vice
More informationJoint Technology Initiative: Innovative Medicine Initiative
Joint Technology Initiative: Innovative Medicine Initiative Dr John E Butler-Ransohoff Global External Innovation and Alliances Bayer HealthCare AG, Berlin/Wuppertal Bari, 30 April 2015 Largest Public
More informationGlobal Oncology Biosimilars Market
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Oncology Biosimilars Market 2016-2020 Global Oncology Biosimilars Market 2016-2020 Publication ID: TNV0216071
More informationThe Patient-Reported Outcome (PRO) Consortium:
The Patient-Reported Outcome (PRO) Consortium: A Collaborative Approach to PRO Instrument Development and Qualification Stephen Joel Coons, PhD Executive Director The views and opinions expressed in the
More informationGetReal: Clinical effectiveness in drug development
GetReal: Clinical effectiveness in drug development Mike Chambers Matthias Egger WP4 Leaders GSK, UK Univ. of Berne, Switzerland BBS/EFSPI Seminar Basel 04Jun13 Egger/Chambers: real world evidence in HTA
More informationM&A Focus: Biotechnology
WWW.IBISWORLD.COM Month 2012 1 Follow on head on Master page A May 2013 M&A Focus: Biotechnology By Anna Son Growing pains from the Patent Cliff will lead Big Pharma companies to invest in promising biotechnology,
More informationCELL-BASED ASSAYS: TECHNOLOGIES AND GLOBAL MARKETS
CELL-BASED ASSAYS: TECHNOLOGIES AND GLOBAL MARKETS BIO080B April 2014 Usha Nagavarapu Project Analyst ISBN: 1-56965-794-7 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More informationFDA Drug Approval Process Vicki Seyfert-Margolis, Ph.D.
Speaker Comparing The Effectiveness Of New Drugs: Should The FDA Be Asking 'Does It Work' Or 'Does It Work Better'? Vicki L. Seyfert-Margolis, PhD Senior Advisor, Science Innovation and Policy U.S. Food
More informationIN VITRO TOXICITY TESTING: TECHNOLOGIES AND GLOBAL MARKETS
IN VITRO TOXICITY TESTING: TECHNOLOGIES AND GLOBAL MARKETS PHM017E January 2014 Robert Hunter Project Analyst ISBN: 1-56965-661-4 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationHistory has Demonstrated that Sub-optimal CDx Strategies can Impact Drug Success
DOES YOUR COMPANION DIAGNOSTIC STRATEGY BEST P OSITION YOU FOR SUCCESS? History has Demonstrated that Sub-optimal CDx Strategies can Impact Drug Success Real-World Examples 1 st Year Sales Increased complexity
More informationLeveraging an Academic-Industry Partnership for Commercial Success
Leveraging an Academic-Industry Partnership for Commercial Success For 115 Years, the Nation s Leading Respiratory Hospital Respiratory Heritage: 115 Years of Respiratory Research and Care Allergy, Asthma,
More informationSingapore offers attractive
Singapore Biotech Guide 2008/2009 Singapore s Biomedical Sciences Landscape companies with spin offs to Singapore, while BMRC takes the lead in coordinating and funding public sector and academic research,
More informationMEDICAL DEVICES: TECHNOLOGIES AND GLOBAL MARKETS
MEDICAL DEVICES: TECHNOLOGIES AND GLOBAL MARKETS HLC170B January 2017 Vijay Laxmi Project Analyst ISBN: 1-62296-410-1 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More informationOn Helix. 02 July Harren Jhoti President & CEO
On Helix 02 July 2014 Harren Jhoti President & CEO Astex Pharmaceuticals Global developer of small molecule drugs for unmet medical needs Expertise in oncology discovery & development World-class fragment-based
More informationPharmaceuticals and Product Stewardship. Sierra Fletcher Product Stewardship Institute April 29, 2011
Pharmaceuticals and Product Stewardship Sierra Fletcher Product Stewardship Institute Who is the Product Stewardship Institute? Non profit founded in 2000 Membership 47 States 200+ Local governments 70+
More informationPartnering & Networks
Partnering & Networks Success drivers in an ever changing and complex health care system Dr. Benedikt Hoffmann, Senior Manger New Business Development & J&J Innovation Manager October 2 nd, 2014 Judith
More information"Stratification biomarkers in personalised medicine"
1/12 2/12 SUMMARY REPORT "Stratification biomarkers in personalised medicine" Workshop to clarify the scope for stratification biomarkers and to identify bottlenecks in the discovery and the use of such
More informationWINNING BRAND VS. GENERIC COMPETITION
WINNING BRAND VS. GENERIC COMPETITION - Competition 2.0: Brands vs. Generics - Winning Beyond the Molecule www.bernardassociatesllc.com Innovator and generic companies are colliding as they invade each
More informationPatients are Counting on Us: It s Time to Act
Patients are Counting on Us: It s Time to Act Brian Johnson Chairman Rx-360 Senior Director Supply Chain Security Pfizer, Inc. 24 th Global GS1 Healthcare Conference October 2, 2013 THE WALL STREET JOURNAL
More informationPersonalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies
Personalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies The value of In Vitro Diagnostics The value of diagnostics as an integral part in the healthcare value chain Diagnostics
More informationA French Biotechnology company dedicated to the development and production of human endocrine cell lines. Innovation In Healthcare April 2012
A French Biotechnology company dedicated to the development and production of human endocrine cell lines Innovation In Healthcare 16-17 April 2012 1 French Biotechnology company Founded in S2 2004 in Paris
More informationStrategic Report. Andy Glowalla, Lead Consultant Elizabeth Davis, Consultant J.R. Hall, Consultant
Strategic Report Andy Glowalla, Lead Consultant Elizabeth Davis, Consultant J.R. Hall, Consultant 19 April 2004 Genentech, Inc. / 2 Background History 3 Products 3 Research & Development 5 Pipeline 5 Manufacturing
More informationMetabolic and Inflammatory Disease R&D:
Insight Pharma Reports Insight Pharma Reports Expert Intelligence for Better Decisions formerly Advances Reports Metabolic and Inflammatory Disease R&D: An Assessment of 5 Highly Promising Therapeutic
More informationSafeSciMET. European Modular Education and Training Programme in Safety Sciences for Medicines
SafeSciMET European Modular Education and Training Programme in Safety Sciences for Medicines What patients need What Europe needs Rapid exploitation of insights in disease mechanisms for introduction
More informationFirst Annual Biomarker Symposium Quest Diagnostics Clinical Trials
First Annual Biomarker Symposium Quest Diagnostics Clinical Trials Terry Robins, Ph.D. Director Biomarker R&D and Scientific Affairs Quest Diagnostics Clinical Trials Key Considerations: Biomarker Development
More informationAs Yogi Berra famously said, When
Delivering Cancer Diagnostics Tools With regulatory changes anticipated but not yet articulated, it s hard to know the best path forward for companies developing cancer diagnostics-related tools and tests.
More informationThe 100,000 Genomes Project Genomics Collaboration Event Finnish Residence
The 100,000 Genomes Project Genomics Collaboration Event Finnish Residence Prof Mark Caulfield FMedSci Chief Scientist for Genomics England Barts Heart Centre William Harvey Research Institute Queen Mary
More informationBIOTECHNOLOGY INDUSTRY
Long-term Prospects of the BIOTECHNOLOGY INDUSTRY Byung-Hwan Hyeon, Ph.D. The Present Situation of the Biotechnology Industry A. Definition and Scope The OECD defines biotechnology as activities that apply
More informationThe Innovative Medicines Initiative (IMI) IMI - Safety Needs and Perspective
The Innovative Medicines Initiative (IMI) IMI - Safety Needs and Perspective Jacky Vonderscher Ph.D. Novartis Head of Exploratory Development in Europe Co-Director of the Predictive Safety Testing Consortium
More informationKlaus Romero MD MS FCP. (Supported by the CAMD AD Modeling & Simulation Team)
Baseline ICV-adjusted Hippocampal Volume as a Biomarker for Enrichment in Alzheimer s Disease Trials Co-Chairs: Patricia Cole (Takeda) & Derek Hill (IXICO) A Modeling Approach to Demonstrate Trial Enrichment
More information1 The biomedical drug, diagnostic, and devices industries and their markets
1 The biomedical drug, diagnostic, and devices industries and their markets Plan Position Patent Product Pass! Production Profits Industry context Market research Intellectual property rights New product
More informationFirst-in-Class Bispecific Antibodies For Cancer Immunotherapy
First-in-Class Bispecific Antibodies For Cancer Immunotherapy 2015 Company Highlights Vision Team Platform Pipeline Partners To dominate the bispecific antibody space in immunooncology through unique pipeline
More informationThe Innovative Medicines Initiative: Building new models of collaborative research across Europe
The Innovative Medicines Initiative: Building new models of collaborative research across Europe Elisabetta Vaudano IMI, Belgium www.imi.europa.eu What is IMI? An European Public-Private Partnership Focused
More informationPharma IP Evergreening Strategies (i.e., Patent Extension) Using Nanotechnology
Pharma IP Evergreening Strategies (i.e., Patent Extension) Using Nanotechnology Jeffrey H. Rosedale, Ph.D Registered U.S. Patent Attorney Partner, Woodcock Washburn LLP, Philadelphia, Pennsylvania Legal
More informationRenub Research Global Molecular Diagnostics Market & Future Forecast
Renub Research www.renub.com Global Molecular Diagnostics Market & Future Forecast 2010 2014 Publisher: Renub Research Published: July, 2011 Global Molecular Diagnostics - Market Overview The global molecular
More informationMOSAIQUES DIAGNOSTICS
MOSAIQUES DIAGNOSTICS CLINICAL PROTEOMICS IN DRUG DEVELOPMENT INFORMATION Clinical Proteomics for early and differential diagnosis FDA Letter of Support Possibilities of a companion test in Drug Development
More informationMarketspace. Keywords: early-stage collaboration, licensing, lead optimisation, lead identification, target validation, drug discovery
Mark J. Belsey spent his PhD looking at the role of cell signalling pathways underlying cell cycle progression in oncology. He is now working for the Competitive Intelligence healthcare team with Datamonitor,
More informationCollaborative Experimental Approaches to Improved Risk Assessment
HESI Application of Genomics to Mechanism-Based Risk Assessment Technical Committee Collaborative Experimental Approaches to Improved Risk Assessment Update: June 2012 Committee Leadership Dr. Jiri Aubrecht
More informationTHE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (GERMAN EDITION)
THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (GERMAN EDITION) Feedback from 60 German patient groups PUBLISHED JUNE 2016 Die neuen, extrem hohen Hepatitis-C- Medikamenten-Preise haben
More informationComments from the FDA Working Group on SUBGROUP ANALYSES. Estelle Russek-Cohen, Ph.D. U.S. Food and Drug Administration Center for Biologics
Comments from the FDA Working Group on SUBGROUP ANALYSES Estelle Russek-Cohen, Ph.D. U.S. Food and Drug Administration Center for Biologics 1 Outline An intro to FDA EMA and FDA on subgroups Companion
More informationBIO OUTSOURCING ASIA Biopharmaceutical Outsourcing Opportunities and Challenges SEPTEMBER 2008 VOL. 1 ISSUE 3
BIO OUTSOURCING ASIA Biopharmaceutical Outsourcing Opportunities and Challenges SEPTEMBER 2008 VOL. 1 ISSUE 3 Bio Outsourcing Asia TABLE OF CONTENTS September 2008 Vol. 1 Issue 3 CanBiotech Inc. CHINA
More informationWill payer leverage and post-election optimism shift dealmaking into a higher gear?
EY M&A Outlook and Firepower Report 2017 Will payer leverage and post-election optimism shift dealmaking into a higher gear? Payer pressure is growing across a wide spectrum of the health care sector.
More informationMeeting Report. Pharma Success in Product Development Does Biotechnology Change the Paradigm in Product Development and Attrition
The AAPS Journal, Vol. 18, No. 1, January 2016 ( # 2015) DOI: 10.1208/s12248-015-9833-6 Meeting Report Pharma Success in Product Development Does Biotechnology Change the Paradigm in Product Development
More informationDelivering on the promise: the clinical application of new diagnoses and treatments for RD K A T E B U S H B Y N E W C A S T L E U N I V E R S I T Y
Delivering on the promise: the clinical application of new diagnoses and treatments for RD K A T E B U S H B Y N E W C A S T L E U N I V E R S I T Y PERSPECTIVE/ DISCLAIMERS Doctor with >24 years experience
More informationWith multiple modalities of care for cancer patients, oncology treatment
Oncology Disruption Demands Strategic Transformation In Vivo Pharma intelligence The rapidly accelerating complexity of oncology drug development demands a new way of doing business. To succeed in this
More informationFor personal use only
Proteomics International Laboratories Ltd Investor Presentation June 2015 Global leader & innovator in the field of proteomics ASX: PIQ 1 Disclaimer and Forward looking statements This Presentation is
More informationThe Lancet Publishes Results from the Landmark Phase III Rivaroxaban Study RECORD2
News Release Bayer HealthCare AG Corporate Communications 51368 Leverkusen Germany Phone +49 214 30 1 www.news.bayer.com Venous Blood Clot Prevention after Hip Replacement Surgery: The Lancet Publishes
More informationUniversità Cattolica del Sacro Cuore
Università Cattolica del Sacro Cuore The role of Regulatory Affairs in drug development Francesco Mazza, Director of Legal, Fiscal & Compliance Affairs in Farmindustria Rome, May 12 2017 Who we are Who
More informationM YRIAD G ENETICS,INC., 320 Wa k a r a Way, S a lt L a ke C i t y, Ut a h 84108, (CONTINUES ON REVERSE SIDE)
M Y R I A D G E N E T I C S, I N C. A N N U A L R E P O R T 2 0 0 4 October 2004 To Our Shareholders, We are pleased to report that Myriad enjoyed another year of both business and scientific achievement.
More informationGENE EXPRESSION REAGENTS MARKETS (SAMPLE COPY, NOT FOR RESALE)
TriMark Publications April 2007 Volume: TMRGER07-0401 GENE EXPRESSION REAGENTS MARKETS (SAMPLE COPY, NOT FOR RESALE) Trends, Industry Participants, Product Overviews and Market Drivers TABLE OF CONTENTS
More informationBiomarkers: Physiological & Laboratory Markers of Drug Effect
Biomarkers: Physiological & Laboratory Markers of Drug Effect Janet Woodcock, M.D. Director, Center for Drug Evaluation and Research Food and Drug Administration January 23, 2014 1 Why Are Biomarkers Important?
More informationTECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT
Specialist in tissue analysis by Histology, Immunohistochemistry and In Situ Hybridization TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT CONTENTS Histalim: who we are Our areas of expertise
More informationE2ES to Accelerate Next-Generation Genome Analysis in Clinical Research
www.hcltech.com E2ES to Accelerate Next-Generation Genome Analysis in Clinical Research whitepaper April 2015 TABLE OF CONTENTS Introduction 3 Challenges associated with NGS data analysis 3 HCL s NGS Solution
More informationGENOMICS WORLD MARKETS (SAMPLE COPY, NOT FOR RESALE)
TriMark Publications May 2008 Volume: TMRGEN08-0515 GENOMICS WORLD MARKETS (SAMPLE COPY, NOT FOR RESALE) Trends, Industry Participants, Product Overviews and Market Drivers TABLE OF CONTENTS 1. Introduction
More informationMICROARRAYS+SEQUENCING
MICROARRAYS+SEQUENCING The most efficient way to advance genomics research Down to a Science. www.affymetrix.com/downtoascience Affymetrix GeneChip Expression Technology Complementing your Next-Generation
More informationEnabling Precision Medicine: The Role of Genetics in Clinical Drug Development A Workshop
A Collaboration between the Forum on Drug Discovery, Development, and Translation and the Roundtable on Genomics and Precision Health Enabling Precision Medicine: The Role of Genetics in Clinical Drug
More informationFactor X. Factor IIa (thrombin)
Protease Inhibitors: Innovation Drives Drug Pipeline Figure 1.2. Schematic of the Coagulation Cascade Tissue damage or inflammation Initiation Factor VIIa / Tissue Factor (TF) Factor IX Factor X Factor
More informationResearched Medicines Industry Association of New Zealand Incorporated. Health Select Committee Submission
Researched Medicines Industry Association of New Zealand Incorporated Health Select Committee Submission Improving New Zealand s environment to support innovation through clinical trials April 2010 Contact
More informationDisclaimer. 2
www.valirx.com 1 Disclaimer This Document comprises an institutional presentation (the Presentation ) which has been prepared by and is the sole responsibility of ValiRx plc (the Company ). The content
More informationCRO partner in Rx/CDx Co-Development
CRO partner in Rx/CDx Co-Development DEDICATED DIALOGUE A sponsored roundtable discussion published in Pharmaceutical Executive Two Covance executives discuss a CRO s role in supporting Companion Diagnostics
More informationSHORT COURSE. Practical Considerations for Biomarker Bioanalysis: Scientific and Regulatory Perspective SUNDAY, SEPTEMBER 17
SHORT COURSE SUNDAY, SEPTEMBER 17 OMNI PROVIDENCE HOTEL PROVIDENCE, RI Practical Considerations for Biomarker Bioanalysis: Scientific and Regulatory Perspective SPONSORED BY: Organized by: www.bostonsociety.org
More informationGrowth Strategies in the Pharmaceutical Industry: Strategic Acquisition
Growth Strategies in the Pharmaceutical Industry: Strategic Acquisition Neal Chatigny Kevin Higginbotham John Walsh Kyle Williams 4/29/2003 Introduction and Statement of Purpose Johnson and Johnson s (J&J)
More informationRegulatory Considerations and Trends Europe and the U.S.
Regulatory Considerations and Trends Europe and the U.S. Professor Kjell Strandberg MD PhD Chairman NDA Advisory Board, NDA Regulatory Science Ltd UK Former CPMP Member and Director General Medical Products
More informationDo We Need Medical Affairs?
Do We Need Medical Affairs? Dr Richard Nieman Head of Medical Affairs, Asia Bayer Healthcare Pharmaceuticals Global R&D Center, Beijing, China May 17, 2011 Biographical Sketch of Dr Richard Nieman Dr Richard
More informationBuilding Biotech Technology Transfer Opportunities
HEALTHCARE Building Biotech Technology Transfer Opportunities Sponsor and developer strategies for success By Alison Sahoo Alison Sahoo Alison Sahoo is a pharmaceutical industry analyst with more than
More informationOracle Buys ClearTrial Adds Leading Cloud-based Clinical Trial Operations and Analytics Applications to the Oracle Health Sciences Suite
Oracle Buys ClearTrial Adds Leading Cloud-based Clinical Trial Operations and Analytics Applications to the Oracle Health Sciences Suite April 12, 2012 Oracle is currently reviewing
More informationMedicine Traceability & AUthenticity
Medicine Traceability & AUthenticity Overview Universidad de Belgrano 18 Mayo, 2010 1 Universidad de Belgrano Medicine Traceability Overview 18 Mayo, 2010 1. A Glance on CTP 2. Introduction 3. Good and
More informationReport from the Paediatric Committee on its first anniversary
European Medicines Agency London, 11 July 2008 Doc. Ref. EMEA/PDCO/347884/2008 Report from the Paediatric Committee on its first anniversary The European Medicines Agency s Paediatric Committee (PDCO)
More informationIndustry Developments in U.S. Biopharmaceutical Contract Services
Industry Developments in U.S. Biopharmaceutical Contract Services February 2010 Industry Developments in U.S. Biopharmaceutical Contract Services February 2010 Copyright 2010 BioCrossroads CICP Foundation
More informationPAREXEL GENOMIC MEDICINE SERVICES. Applying genomics to enhance your drug development journey
PAREXEL GENOMIC MEDICINE SERVICES Applying genomics to enhance your drug development journey YOUR JOURNEY. OUR MISSION. Genomic expertise to simplify the route to product approval and maximize patient
More informationBiogen Idec Synergy Creation in the move to the Big League. Activities, Assets and Sales Figures
Biogen Idec Synergy Creation in the move to the Big League Activities, Assets and Sales Figures Biogen Idec is one of the few integrated firms in the biotechnology industry that manages a drug right from
More informationReimbursement Strategy for Companion Diagnostics:
Reimbursement Strategy for Companion Diagnostics: Emerging Models and Requirements Edward E. Berger, Ph.D. Larchmont Strategic Advisors Definition Companion diagnostic A diagnostic test used to predict
More informationCurrent Status of Pharmaceutical Patenting at United States Patent Office Rau. B. S Appaji P. V
Current Status of Pharmaceutical Patenting at United States Patent Office Rau. B. S Appaji P. V Abstract: Indian pharmaceutical industry has proved manufacture of global quality pharmaceutical products
More informationAdaptive Clinical Trials
MARCH 22 23, 2018 WYNDHAM PHILADELPHIA HISTORIC DISTRICT PHILADELPHIA, PA Adaptive Clinical Trials SYMPOSIUM Analyze Statistics, Data Management, and Operations to Improve Clinical Performance FEATURED
More informationHelping Pharmas Manage Compliance Risks for Speaker Programs
COGNIZANT 20-20 Helping Pharmas Manage Compliance Risks for Speaker Programs By taking a rigorous and thoughtful approach that pivots around key performance indicators, pharmaceuticals companies can proactively
More informationLili M. Portilla, MPA Acting Director, Office of Policy, Communications and Strategic Alliances National Center for Advancing Translational Sciences
Lili M. Portilla, MPA Acting Director, Office of Policy, Communications and Strategic Alliances National Center for Advancing Translational Sciences (NCATS), NIH GUIRR Meeting, October 9, 2012 Established
More informationWITA/GWU TRADE SEMINAR September 29, 2016 Washington D.C. RICHARD KJELDGAARD INTELLECTUAL PROPERTY AND TRADE CONSULTANT
WITA/GWU TRADE SEMINAR September 29, 2016 Washington D.C. RICHARD KJELDGAARD INTELLECTUAL PROPERTY AND TRADE CONSULTANT Pharmaceutical IP Policy Issues Economics - Business Model IP TPP Global Challenges
More informationGenomics And Pharmacogenomics In Anticancer Drug Development And Clinical Response (Cancer Drug Discovery And Development)
Genomics And Pharmacogenomics In Anticancer Drug Development And Clinical Response (Cancer Drug Discovery And Development) Strategies for modern biomarker and drug - Oct 3, 2014 Sequencing the cancer genome
More informationType of Activity. Universal Activity Number L04-P
Below are the pharmacy designated Universal Activity Numbers (UANs) and type of activity that is applicable for each of the following program offerings Session # Title 104 Impact of Biologics, Vaccines,
More informationREIMAGINING DRUG DEVELOPMENT:
Biology Reconstructed REIMAGINING DRUG DEVELOPMENT: Accurate Disease Modeling To Drive Successful Therapies Julia Kirshner, CEO julia@zpredicta.com 1 SUCCESS RATES OF DRUG DEVELOPMENT ARE LOW, " PARTICULARLY
More informationLehman Brothers Global Healthcare Conference
Lehman Brothers Global Healthcare Conference Lawrence S. Olanoff - MD, Ph.D President and Chief Operating Officer March 20, 2007 Safe Harbor Except for the historical information contained herein, this
More informationPharmaceutical and Biotechnology Construction Sector Report - UK Analysis
Pharmaceutical and Biotechnology Construction Sector Report - UK 2016-2020 Analysis Published: 16/09/2016 / Number of Pages: 98 / Price: 795.00 Introduction and Overview The 3rd edition of the report'pharmaceutical
More informationEU perspective: European procedure for Qualification of novel methodologies for medicine development. Elmer Schabel MD
EU perspective: European procedure for Qualification of novel methodologies for medicine development Elmer Schabel MD Nothing to disclose See: http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/landing/ex
More informationTuberculosis Drug Accelerator
Tuberculosis Drug Accelerator Overview of Activities and Portfolio who, why, what, how, by when and where are we now Steve Berthel 1 What is the Tuberculosis Drug Accelerator? The A is a groundbreaking
More informationImproving the productivity of drug development: How can adaptive designs help? Richard Peck, Global Head Clinical Pharmacology, Roche Products Ltd
Improving the productivity of drug development: How can adaptive designs help? Richard Peck, Global Head Clinical Pharmacology, Roche Products Ltd The Cost of Drug Development Eli Lilly R&D Productivity
More informationPharmaceutical Reviews Year: 2008 Vol: 6 Issue: 1 ISSN: School of Pharmacy and Technology Management, NMiMS University, Mumbai
Dayanidhi B, Amol S School of Pharmacy and Technology Management, NMiMS University, Mumbai The US$65-billion (in 2005), global R&D pie is expected to grow to US$l00-billion by 2010. If India secures even
More informationPersonalized. Health in Canada
Personalized Health in Canada Canadian Institutes of Health Research Personalized Medicine Signature Initiative 2010-2013 0 Dr. Morag Park CIHR Institute of Cancer Research Dr. Paul Lasko CIHR Institute
More informationTerminology for personalized medicine
Terminology for personalized medicine Sarah Ali-Khan 1 PhD, Stephanie Kowal 2, Westerly Luth 2, Richard Gold 1 SJD, and Tania Bubela 2 PhD JD 1. Centre for Intellectual Property Policy (CIPP), Faculty
More informationPrincipal approach to CPV :
Principal approach to CPV : Integration with Quality Systems & Operating Mechanisms J. Gampfer, Baxalta, Vienna Austria Baxalta Principal Approach to CPV J. Gampfer Page 1 Baxalta Principal Approach to
More informationPOST-ASH Issue 2, Bendamustine/Rituximab and Maintenance Lenalidomide in Relapsed/Refractory CLL and SLL
POST-ASH Issue 2, 2013 Bendamustine/Rituximab and Maintenance Lenalidomide in Relapsed/Refractory CLL and SLL For more visit ResearchToPractice.com/5MJCASH2013 CME Information OVERVIEW OF ACTIVITY The
More informationNPV Model and Analyzer
July 2015 NPV Model and Analyzer User Guide to Methodology X STRICTLY CONFIDENTIAL PAGE 2 JULY 2015 Table of Contents TABLE OF CONTENTS... 2 OVERVIEW... 3 INTRODUCTION... 3 NPVS FROM EVALUATEPHARMA ALPHA...
More informationDOI: /CIRCULATIONAHA
Optimizing Trial Design: Sequential, Adaptive, and Enrichment Strategies Cyrus Mehta, Ping Gao, Deepak L. Bhatt, Robert A. Harrington, Simona Skerjanec and James H. Ware Circulation 2009;119;597-605 DOI:
More informationGlobal In-Vitro Diagnostic Market Report
Global In-Vitro Diagnostic Market Report ----------------------------------------------------- 2013 Executive Summary The process of performing a diagnostic test outside of a living organism in an artificial
More informationIndustry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development
Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development Aernout van Haarst PhD Director, European Corporate Development Feb 2016 Industry Academic Collaboration
More information